(PharmaNewsWire.Com, April 10, 2020 ) This market is expected to reach USD 25.20 Billion by 2021 from USD 17.20 Billion in 2016, at a CAGR of 7.9%.
A number of factors such as rising geriatric population, regulatory approval for new and advanced electroceuticals, growing investments and funds for the development of novel therapies and electroceuticals, rising prevalence of neurological disorders, and growing prevalence of hearing loss are expected to drive the growth of the electroceuticals/bioelectric medicine market during the forecast period.
In this report, the global electroceuticals/bioelectric medicine market is segmented on the basis of product, type of device, application, end user, and region. Based on product, the electroceuticals/bioelectric medicine market is categorized into implantable cardioverter defibrillators, cardiac pacemakers, spinal cord stimulators, cochlear implants, deep brain stimulators, transcutaneous electrical nerve stimulators, vagus nerve stimulators, sacral nerve stimulators, retinal implants, and other electrical stimulators (gastric electrical stimulators, transcranial magnetic stimulators, and respiratory electrical stimulators). The implantable cardioverter defibrillators segment is expected to account for the largest share of the electroceuticals/bioelectric medicine market in 2016. However, the retinal implants segment is projected to grow at the highest CAGR during the forecast period.
Based on type of device, the electroceuticals/bioelectric medicine market is segmented into implantable electroceutical devices, and non-invasive electroceutical devices. The implantable electroceutical devices segment is expected to account for the largest share of the market in 2016; while, the non-invasive electroceutical devices segment is projected to grow at the highest CAGR in the forecast period.
Based on application, the electroceuticals/bioelectric medicine market is segmented into product wise such as cardiac pacemakers and implantable cardioverter defibrillators (used for arrhythmia), cochlear implants (used for sensorineural hearing loss), retinal implants (used for retinal pigmentosa), spinal cord stimulators (used for chronic pain, failed back surgery, and ischemia), deep brain stimulators (used for Parkinsons disease, tremors, depression, and others), sacral nerve stimulators (used for urine incontinence and fecal incontinence), vagus nerve stimulators (used for epilepsy and other conditions), transcutaneous electrical nerve stimulators (used for treatment-resistant depression and others), and other electric stimulators (used for gastro paresis, obesity, depression, migraine headaches, and spinal cord injuries).
On the basis of end user, the electroceuticals/bioelectric medicine market is segmented into hospitals, research institutes, and individual users. The hospitals segment is expected to account for the largest share of the market in 2016; while, the individual users segment is projected to grow at the highest CAGR in the forecast period.
Geographically, the global electroceuticals/bioelectric medicine market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America, Middle East, and Africa). North America is expected to account for the largest share of the electroceuticals/bioelectric medicine market in 2016, followed by Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific market is projected to grow at the highest CAGR, and serves as a revenue pocket for companies offering electroceuticals/bioelectric medicine devices.
Prominent players in the global electroceuticals/bioelectric medicine market include Medtronic plc (Ireland), St. Jude Medical, Inc. (U.S.), Boston Scientific Corporation (U.S.), Cochlear Limited (Australia), Sonova Holding AG (Switzerland), LivaNova PLC (U.K.), Biotronik (Germany), Nevro Corporation (U.S.), Second Sight Medical Products, Inc. (U.S.), and ElectroCore LLC (U.S.).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
